Changes in emergency department visits for zolpidem-attributed adverse drug reactions after FDA Drug Safety Communications.

ABSTRACT:

Purpose

To identify possible changes in U.S. emergency department (ED) visits from zolpidem-attributed adverse drug reactions (ADRs) after 2013 Food and Drug Administration (FDA) Drug Safety Communications (DSCs), which notified the public about FDA's new dosing recommendations for zolpidem.

Methods

We estimated the occurrence of ED visits from zolpidem-attributed ADRs using nationally representative, public health surveillance of medication harms (National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project, 2010-2017). We estimated the number of zolpidem prescriptions using IQVIA National Prescription Audit, 2010-2017. We calculated rates of ED visits for zolpidem-attributed ADRs per 10 000 dispensed zolpidem prescriptions and identifi

SUBMITTER: Geller AI 

PROVIDER: S-EPMC7263461 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature